What is Ring Therapeutics?
Founded in 2017, Ring Therapeutics is dedicated to advancing the therapeutic potential of Anellovectors. The company is building an in-house manufacturing capability to rapidly scale production to commercial levels. This strategic focus aims to transition the Anellovector platform from research and development to clinical application, addressing a critical need in the biotechnology sector for efficient and scalable gene therapy manufacturing.
How much funding has Ring Therapeutics raised?
Ring Therapeutics has raised a total of $203.5M across 2 funding rounds:
Series B
$117M
Series C
$86.5M
Series B (2021): $117M with participation from Partners Investment, UPMC Enterprises, Altitude Life Science Ventures, and Invus
Series C (2023): $86.5M led by CJ Investment and Altitude Life Science Ventures
Key Investors in Ring Therapeutics
CJ Investment
CJ Investment is a venture capital firm that operates in the Venture Capital & Private Equity industry, focusing on early-stage companies. The firm is headquartered in Tacoma, Washington.
Altitude Life Science Ventures
Altitude Life Science Ventures is a venture capital firm located in Kirkland, WA, specializing in investments in early-stage life science companies. The firm focuses on supporting innovative ventures within the life sciences sector.
Partners Investment
Undisclosed investor participating in the funding round.
What's next for Ring Therapeutics?
The recent major strategic investment signals a pivotal growth phase for Ring Therapeutics. This capital infusion is expected to accelerate the company's efforts in scaling its manufacturing operations and further exploring the broad therapeutic applications of its Anellovector technology. Ring Therapeutics is poised to leverage this financing to advance its platform from bench to bedside, aiming to make significant strides in the gene therapy market.
See full Ring Therapeutics company page
